Preclinical and clinical studies of stem cell transplantation in neurological disorders
Type of stem cells | Neurological disorders | References | Models | Administration’s route | Quantity of stem cells | Effects | Risks |
---|---|---|---|---|---|---|---|
NSCs | Parkinson’s disease | [41, 44] | Rats | IV, IC | 2 × 106 cells | Ameliorated Parkinson dyskinesia and promoted neurogenesis | Risk of cancer development |
Huntington’s disease | [96] | Primate, rats | Transplanted into brain | 5 × 104–1 × 106 cells | Reduction of lesion size and proliferation in the striatum | ||
Stroke | [45] | Mice | Transplanted into brain | 2 × 105 cells | Improved sensorimotor functioning and reduced infarct size | ||
[97] | Human | IC | 2 × 106 cells | It has been shown to be safe and effective in improving NIHSS scale | |||
IV | Escalation dose from 3 × 105–1 × 107 cells | Induces neurogenesis in the human brain | |||||
TBI | [46] | Mice | Transplanted into brain | 2.5 × 105–2 × 107 cells | Early transplant showed an enhanced functional recovery, while a delayed transplantation seems to be more controversial | ||
Amyotrophic lateral sclerosis | [47] | Mice, rats | IV | 2.5 × 105–1 × 106 cells | Increased life span, improvement in motor neuron survival and slow down disease progression | ||
[98] | Human | Transplanted in the spinal cord, transplanted in the motor frontal cortex | 5 × 106–1.6 × 107 cells | Improved the life span and reduced disease progression | |||
Alzheimer’s disease | [99] | Rats, mice | Transplanted into brain | Rats: 1 × 105–1 × 106 cells; mice: 1.5 × 104 cells | Enhanced synaptogenesis and improved learning and memory | ||
ESCs | Parkinson’s disease | [100] | Mice, rats, monkey | IC | Mice: 1.5 × 105 cells; rats: 2.5 × 105 cells; monkey: 7.5 × 106 cells | Neuroprotection and neurogenesis | Tumor formation; ethical issue |
Huntington’s disease | [101] | Mice | Transplanted into brain | 1 × 105 cells | Reduction in cerebral lesion size and proliferation in the striatum | ||
Multiple sclerosis | [101] | Mice, rats | Intraventricular | 1 × 106 cells | Consistent beneficial effect | ||
Human | IV | Not specified | Inconsistent results | ||||
Alzheimer’s disease | [19, 20, 102] | Mice, rats | Transplanted into brain | 1 × 105–1 × 106 cells | Improved learning and memory | ||
iPSCs | Parkinson’s disease | [103] | Mice | Transplanted into brain | 1.5 × 105 cells | Neuroprotective and neurogenesis | Risk of cancer and teratoma formation |
Huntington’s disease | [45, 104, 105] | Rodent | IV, transplanted into brain | 1 × 106 cells | Migration to striatum and differentiation into glial cells | ||
TBI | [56] | Rats | IV | 2 × 106–1 × 107 cells | Long-term improvement in spatial learning and attenuation of neuroinflammation | ||
Amyotrophic lateral sclerosis | [57] | Mice | In culture cells as well as in mice | 1 × 106 cells | Increased life span | ||
Alzheimer’s disease | [26] | Transgenic mice | Transplanted into brain | Not specified | Reduction of brain amyloid beta | ||
MSCs | Parkinson’s disease | [36] | Human | IV | 1 × 106 cells | Exert therapeutic effect by protecting dopaminergic neurons and maintaining the nigrostriatal pathway | Short survival time of the cells; homing issues |
[106] | Mice | Transplanted into brain | Not specified | Subjective improvement of the gait and the facial symptoms | |||
Stroke | [66] | Mice, rats | IC, IV | 1 × 108 cells | Improved sensorimotor functioning and reduced infarct size | ||
[67] | Human | IV | |||||
TBI | [107] | Rats | Transplanted into brain | 3 × 105–4 × 106 cells | Reduced inflammatory cytokines, reactive astrogliosis, and edema | ||
Amyotrophic lateral sclerosis | [38, 108] | Human, mice | IV | 1.7 × 107 cells | Positive safety outcome and increased life span | ||
Multiple sclerosis | [48] | Mice, rats | Transplanted into brain | 2 × 107 cells | Alleviated symptoms and positive effect on cytokines | ||
[38] | Human | IV | 2.5 × 106 cells | Safe and improvement of symptoms | |||
Alzheimer’s disease | [35] | Mice | Intracerebroventricular, IC, IV | Not specified | Improved cognitive function and reduced amyloid beta | ||
SCI | [64] | Rats | IC, IV | Not specified | Improve motor recovery | ||
[51] | Human | IV | 8 × 105–4 × 108 cells | Improve sensory and motor score |
IV: intravenous; NIHSS: National Institutes of Health Stroke Scale
SHI: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation.
The author declares that he has no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.